fogsprayhk
Berobenatide | CAS 3028974-74-2 | GLP-1 Receptor Agonist for Metabolic and Endocrine Research
Product Description
Berobenatide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), designed to selectively activate GLP-1 receptors with enhanced metabolic stability and receptor affinity. As a GLP-1 receptor agonist, Berobenatide exerts its activity through the incretin hormone pathway, playing a central role in glucose homeostasis and insulin regulation.
The compound’s design incorporates strategic amino acid modifications that confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), thus extending its biological half-life compared with native GLP-1. This increased stability allows for prolonged receptor activation and sustained downstream signaling in experimental models.
Berobenatide functions by binding to the GLP-1 receptor (GLP1R), a G protein–coupled receptor predominantly expressed in pancreatic β-cells, the gastrointestinal tract, and certain regions of the central nervous system. Upon activation, GLP1R initiates cAMP-dependent signaling cascades that promote insulin synthesis, enhance insulin secretion in a glucose-dependent manner, and suppress glucagon release.
In laboratory research, Berobenatide is used to investigate glucose-stimulated insulin secretion (GSIS), pancreatic β-cell protection, appetite regulation, and lipid metabolism. It is also employed in in vitro cell-based assays and in vivo rodent models to study incretin receptor dynamics, receptor internalization, and downstream metabolic adaptations.
Berobenatide | CAS 3028974-74-2 | GLP-1 Receptor Agonist for Metabolic and Endocrine Research
Product Description
Berobenatide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), designed to selectively activate GLP-1 receptors with enhanced metabolic stability and receptor affinity. As a GLP-1 receptor agonist, Berobenatide exerts its activity through the incretin hormone pathway, playing a central role in glucose homeostasis and insulin regulation.
The compound’s design incorporates strategic amino acid modifications that confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), thus extending its biological half-life compared with native GLP-1. This increased stability allows for prolonged receptor activation and sustained downstream signaling in experimental models.
Berobenatide functions by binding to the GLP-1 receptor (GLP1R), a G protein–coupled receptor predominantly expressed in pancreatic β-cells, the gastrointestinal tract, and certain regions of the central nervous system. Upon activation, GLP1R initiates cAMP-dependent signaling cascades that promote insulin synthesis, enhance insulin secretion in a glucose-dependent manner, and suppress glucagon release.
In laboratory research, Berobenatide is used to investigate glucose-stimulated insulin secretion (GSIS), pancreatic β-cell protection, appetite regulation, and lipid metabolism. It is also employed in in vitro cell-based assays and in vivo rodent models to study incretin receptor dynamics, receptor internalization, and downstream metabolic adaptations.